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Abstract
Antibiotic-associated diarrhea (AAD) and Clostridum difficile infections (CDI) have been well studied for adult cases, but not as well in the pediatric population. Whether the disease process or response to treatments differs between pediatric and adult patients is an important clinical concern when following global guidelines based largely on adult patients. A systematic review of the literature using databases PubMed (June 3, 1978 (June 3, -2015 was conducted to compare AAD and CDI in pediatric and adult populations and determine significant differences and similarities that might impact clinical decisions. In general, pediatric AAD and CDI have a more rapid onset of symptoms, a shorter duration of disease and fewer CDI complications (required surgeries and extended hospitalizations) than in adults. Children experience more community-associated CDI and are associated with smaller outbreaks than adult cases of CDI. The ribotype NAP1/027/BI is more common in adults than children. Children and adults share some similar risk factors, but adults have more complex risk factor profiles associated with more co-morbidities, types of disruptive factors and a wider range of exposures to C. difficile in the healthcare environment. The treatment of pediatric and adult AAD is similar (discontinuing or switching the inciting antibiotic), but other treatment strategies for AAD have not been established. Pediatric CDI responds better to metronidazole, while adult CDI responds better to vancomycin. Recurrent CDI is not
INTRODUCTION
Clinical presentation and response to treatments often differ radically in pediatric compared to adult patient populations. Although antibiotic-associated diarrhea (AAD) and Clostridium difficile (C. difficile) infections (CDI) are widely studied in adult populations, a comparison of the disease processes in the pediatric population is not as well described, especially for C. difficile infections [1] . If pediatric and adult patients respond differently to therapies for these conditions, this may be an important clinical concern, as global guidelines are typically based on adult patients, not children [2, 3] . Results from clinical trials performed in adults might be extrapolated to pediatric populations if the response is similar in these two populations. Currently, there are limited comprehensive comparisons of these two populations for AAD and CDI. The national prevalence of both pediatric [4] [5] [6] and adult cases of CDI [7, 8] are increasing over time, but the secular trends for pediatric and adult rates of AAD have not been documented. The impact of AAD and CDI on healthcare systems is high. In the United States, 453000 cases of incident CDI occurred in 2013, associated with 29300 deaths and increased costs of healthcare from $3427-$9960/patient [9, 10] . Many incident cases of adult CDI will recur (up to 136000/ year) and these cases are associated with higher costs ($11631/case) [10] . The burden and costs of pediatric AAD have not been documented by national surveillance studies. AAD is also associated with longer hospitalizations, higher healthcare costs, increased risks of mortality and acquiring other nosocomial infections [11] . The aim of this review is to update the literature and compare AAD and CDI in pediatric and adult populations and determine significant differences and similarities that might impact clinical decisions.
DEFINITIONS

Pediatric vs adult
Generally for AAD, the pediatric population is defined as aged one month to 18 years of age, but for pediatric CDI, the reported age range shifts to 1-21 years old [1, [12] [13] [14] . For pediatric CDI, infants younger than one year old are typically excluded from being defined as CDI cases due to their high asymptomatic carrier rate associated with the lack of toxin A/B receptors in the immature colon and high prevalence of other etiologies of diarrhea (most commonly viral causes) [15] . Adults are usually defined as ≥ 21 years old, but published studies have included ages as young as 16 years old. The lower limit for pediatric AAD is difficult to define without knowing more about asymptomatic carriage of other etiologies of AAD. Although it is appreciated that the intestinal microbiome is in an active stage of change during early life, few studies report clinical data by finer age strata other than either pediatric or adult. For this review, we include all ages under 21 years as pediatric AAD and ages 1-21 years old as pediatric CDI.
Diarrhea
The World Health Organization defined diarrhea in adults and children as "the passage of three or more loose or liquid stools per day, or more frequently than is normal for the individual" [16] . In clinical studies, diarrhea in adults is usually defined as ≥ 3 liquid stools/d for at least two days [2, 17] . Pediatric diarrhea is typically defined using the WHO definition [16] , but one study defined pediatric diarrhea as ≥ 5 stools/d [18] .
Antibiotic-associated diarrhea
AAD is defined as diarrhea associated with antibiotic exposure, either while on antibiotics or for up to eight weeks after antibiotics have been discontinued [19, 20] Although the etiologies for AAD are varied and not all the pathogens are identifiable, nearly one-third of AAD cases are due to C. difficile. In pediatric AAD, etiologies may include viruses (25% in one study) [21] or C. difficile (22%-30%), but also may be due directly to osmotic imbalances in the intestines brought about by antibiotic exposure and microbiota disruption. In adults with AAD, identifiable pathogens include C. difficile (13%-28%), C. perfringens (3%-21%), Staphylococcus aureus (1%-28%) and less commonly Klebsiella oxytoca [22] [23] [24] [25] [26] [27] .
C. difficile infections
CDI diagnosis is based on standard definitions in practice guidelines, which are based on a positive result in two factors: (1) presence of C. difficile in the stool (e.g., microbial culture, cytotoxin assay, enzyme immunoassay, nucleic acid amplication test, or polymerase chain ribotyping); and (2) the presence of gastrointestinal symptoms (e.g., diarrhea, colitis, etc.) without another etiology being present [2, 28, 29] .
While there is no standard definition of severe CDI, most experts agree that severe CDI should include at least one of the following: elevated leukocyte counts, elevated creatinine, albumin counts, intensive care unit admission, surgery or pseudomembranous colitis [2] .
Onset of symptoms
Laboratory testing and surveillance data allows both the setting (location of disease onset) and the time of onset (incubation time) to be determined. If an etiology can be determined (e.g., C. difficile), the source of the infection may be determined. AAD or CDI cases may begin exhibiting symptoms at healthcare settings (including hospitals and long-term care facilities) or in community settings (home, daycares, etc.), but the setting is typically only defined for CDI cases. The incubation time for AAD (defined as the time between antibiotic initiation and the onset of diarrhea) falls into two groups: early onset, occurring during antibiotics and delayed onset, which may occur from 2-8 wk after the antibiotics have been discontinued [30, 31] . The incubation time for CDI should best be measured from the first day of the inciting antibiotic to the first day of diarrhea associated with a positive C. difficile assay, but most studies of CDI have not collected data related to the first day of antibiotic for all their patients. As a consequence, the incubation time for CDI is typically measured starting from either the first day of healthcare facility admission or first positive laboratory test for C. difficile and ending at the first day of defined diarrhea. Healthcare facility-associated (HCFA) cases are assumed to have acquired C. difficile either during their current stay or during a previous recent stay at a healthcare facility within the previous 12 wk. The onset of HCFA cases may be either during their current stay (healthcare-onset) or after discharge (communityonset). Community-acquired CDI (CA-CDI) cases are defined as a symptom onset in the community with no associated healthcare facility exposure in the prior 12 wk, or onset ≤ 48 h of a current hospital admission and the last discharge from a healthcare facility beyond 12 wk of the admission [2] .
EPIDEMIOLOGY
Incidence and setting
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States national surveillance data show continued increases in the rates of adult CDI from 2000-2013 [7, 8] . Elderly patients in long-term care facilities are also experiencing increasing CDI rates [46] . The reported median age of adult CDI ranges from 59-77 years old (Table 1) . Most cases (47%-67%) of adult CDI are female, while ethnicity or race data is rarely reported in studies of adult CDI.
Outbreaks
Pediatric AAD outbreaks: Few outbreaks of pediatric AAD have been reported in children < 2 years old. Of 65 children in daycares who were followed for 3.5 mo., five outbreaks of diarrhea occurred (n = 21 developed diarrhea), and while most (62%) were due to C. difficile, eight (38%) had no known etiology [41] . There are few other reports of pediatric AAD outbreaks excluding those with CDI.
Adult AAD outbreaks:
The difficulty of determining outbreaks of AAD is that early reports in the literature of outbreaks may have been due to C. difficile, but were missed as testing was not standard before 1980' s. In addition, the lack of assays for other etiologies of AAD has limited documentation of AAD outbreaks. One study of adult inpatients with diarrhea, 591/4659 (13%) of AAD cases were due to C. difficile, 155 (3%) due to Clostridum perfringens and 10 (0.2%) due to Staphylococcus aureus. No clustering of C. perfingens or S. aureus DNA fingerprints was found to indicate an outbreak situation [22] . Pediatric CDI outbreaks: A few, small CDI outbreaks involving 6-13 children have been reported [41, 47, 48] . Despite a high rate of C. difficile carriage in several pediatric patient studies [39, 49] , large CDI outbreaks were found to be uncommon. An epidemiological study at a Belgian pediatric hospital found asymptomatic carriage of C. difficile was common (76/114, 67% were positive for C. difficile) but only 13 children developed CDI and 2 developed necrotizing enterocolitis, and no evidence of CDI outbreaks were observed. Clustering of serogroups B and C were observed, but most were asymptomatic carriers [49] .
A hypervirulent strain of C. difficile (NAP1/027/BI) is responsible for outbreaks in adults, but is detected only rarely in pediatric CDI populations [50] , and not found by others [38, [51] [52] [53] , making its contribution to disease in children less certain than in adults. In a study, of 28 isolates of C. difficile isolated from children, eight different genotypes were seen, but none were 027 ribotype [52] . While in most studies of pediatric CDI, < 20% of isolates are the hypervirulent strain (Table 1) , a few studies found higher frequencies of this ribotype. NAP1/027/BI isolates were found in 19% of 195 samples from children hospital isolates (median age of 2.5 years old) [50] and in 20% of pediatric cases in Poland [18] . Most studies find ribotype 014 is the most common strain isolated from pediatric CDI cases. Two studies in New Zealand and Australia reported ribotype 014 was the most commonly isolated (37% and 48%, respectively) [38, 54] and also from a study in Germany (26%) [55] .
Adult CDI outbreaks:
The notoriety of CDI is due to its ability to cause large outbreaks of disease in adults at healthcare facilities that are difficult to control without a multidisciplinary infection control programs. Nosocomial outbreaks have been reported in adult inpatients since the 1980s, with as few as 15 cases to as many as 1703 (Table 1 ) [55] [56] [57] [58] . Large outbreaks of CDI occurred in 12 Canadian hospitals in Quebec providence during 2004 (n = 1703 CDI cases) which were associated with high mortality and the increased incidence was associated with the emergence of a hypervirulent strain of C. difficile typed as NAP1/027/ BI [57] . A large outbreak of CDI with 253 adult nosocomial cases was reported at a teaching hospital following increased fluoroquinolone use [59] . Jump et al [60] reported outbreaks of CDI in five hospitals during 2006 in Ohio, totally 1269 cases and 66% of the isolates were typed as NAP1/027/BI. However, other strain types of C. difficile are also responsible for outbreaks. During one outbreak at a Hong Kong rehabilitation ward, 80% of 15 cases of adult CDI at were due to ribotype 02 [61] . NAP1/027/BI C. difficile strains continue to be responsible for outbreaks of CDI in adult patients, particularly elderly patients in Canada and this serotype is now frequently isolated in adults globally (Table 1) [57, 62] .
Risk factors
Pediatric AAD risk factors: Risk factors for AAD may broadly be divided into two modalities: host factors (e.g., age) and disruptive factors (e.g., antibiotics) that may disturb the normally protective intestinal microbiome [1, 20] . The two main risk factors for pediatric AAD are age (1-2 years old) and type of antibiotic exposure, as shown in Table 2 . In one study of 650 outpatient children on oral antibiotics, symptomatic pediatric AAD occurred in 18% of outpatient children aged 1-2 years old and in 3% for older children (3-16 years) [63] . The incidence of AAD may be even higher (60% to 70%) if broad-spectrum antibiotics (cephalosporins, penicillins, etc.) were used. The number of controlled studies determining risk factors for pediatric AAD is limited. Few other risk factors for pediatric AAD have been established.
Adult AAD risk factors:
Most studies determining risk factors for AAD have focused on the most common etiology of AAD, namely C. difficile. Literature is limited for risk factors of non-C. difficile AAD cases. One study prospectively followed 4659 adult inpatients for AAD and found 13% were due to C. difficile, 3% were due to Clost. perfringens and 0.2% were due to S. aureus [22] . Risk factors for adult C. perfringensassociated AAD included: age > 80 years (OR = 13.7), female gender (OR = 2.0) and antacid use (OR = 2.8) [22] . Another study of adult patients with AAD found age > 80 years, previous antibiotic use (OR = 2.3) and proton-pump inhibitor use (OR = 2.0) increased the risk of AAD, but co-morbidities or surgery had no effect on the risk of AAD [37] .
Pediatric CDI risk factors:
In contrast to AAD, there are numerous studies for CDI risk factors (Table 2) . Risk factors for CDI involve a triad of factors: (1) host factors (e.g., age, gender, co-morbidities); (2) factors disruptive of the protective intestinal microbiome (e.g., antibiotics, surgery, other medications, nasogastric tube feeding, gastrostomy); and (3) increased exposure to C. difficile spores (e.g., longer healthcare facility stays, prior admissions, infected room-mates) [64, 65] . However, not all factors act equally in the pediatric vs adult populations. The risk factors that are common for pediatric CDI include: age 1-4 years old, co-morbidities (especially cancer and inflammatory bowel disease), exposure to antibiotics within the prior 12 wk (particularly multiple antibiotics, cephalosporins, and penicillins), and prior or current hospitalization (Table 2 ) [38, [66] [67] [68] [69] . Conversely, risk factors for pediatric CA-CDI are not as strongly associated with antibiotic exposure [70] . From the CDC Emerging Infections Program, data from 10 United States states from 2010-2011 found 71% of the 944 of pediatric CDI cases were CA-CDI and of these, 67% had no antibiotic exposure in the two weeks prior to CA-CDI diagnosis [4] . The five studies that show the highest rate of no prior antibiotic exposures (19%-67%) were largely CA-CDI pediatric cases (Table 2) [4, 12, 40, 70, 71] . In a study of 202 children with CDI, CA cases were found to have less co-morbidities (74% vs 98%) and less antibiotic exposure (42% vs 77%) than HCFA cases, Turck [63] > 70 yr Elseviers [37] 1-4 yr Tai [67] > 65 yr Hu [189] > 70 yr Asha [22] 6 mo-2 yr McFarland [1] > 65 yr Beaulieu [190] > 65 yr Vardakas [74] > 65 yr Pepin [106] > 65 yr McFarland [89] > 85 yr Vesteinsdottir [73] Yes (RR = 1.2) Eyre [118] Yes (HR = 1.4) Marwick [191] Comorbidity NR No Elseviers [37] Yes (OR = 1.1) Sammons [44] Yes (OR = 1.3) McFarland [121] Yes (OR = 1.1) Tai [67] Yes (OR = 4) Wenisch [102] Yes (OR = 2.0) Samady [68] No Tabak [117] No Vesteinsdottir [73] Chemotherapy NR No Elseviers [37] Yes (HR = 1.9) de Blank [69] Yes (OR =2.3) Dubberke [192] or cancer Yes (OR = 3.8) Tai [67] Yes (OR = 3.6) Huang [65] Yes (RR = 2.7) Sathyendan [38] IBD NR No Elseviers [37] Yes (OR = 11.4) Hourigan [187] Yes (OR = 3.3) Hourigan [187] Yes (OR = 11.4) Nyland [14] No Leung [179] Yes (OR = 4.5) Kelsen [188] Prior GI condition
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Adult CDI risk factors:
The risk factors that are common for adult CDI also include the same triad of factors (Table 2) : host factors (age, co-morbidities), disruptive factors (exposure to antibiotics or other medications) and increased exposure to C. difficile spores (prolonged lengths of stay at healthcare facilities). A broader range of antibiotics have been identified as high-risk in adults, but there are not as many studies done in children (Table 2) . However, many additional types of risk factors were identified in several studies using multivariate models to adjust for other simultaneous risk factors. These included enemas (aRR = 3.3), gastrointestinal stimulants (aRR = 3.1), stool softeners (aRR = 1.7) [64] , cytoxic drugs (aRR = 8.1), feeding tubes (aRR = 2.8) [22] , albumin level < 2.7 mg/dL (aOR = 3.8), leukocytosis [WBC count > 13000 cells/mL (aOR = 2.7), impaired functional capacity (independent was baseline vs required assistance or bedridden, aOR = 9.14), watery diarrhea (aOR = 17.4) [25] , and mechanical ventilation (aOR = 1.9) [73] . A meta-analysis pooled data from five studies of adult CDI and found the same risk factors associated with BI/NAP1/027 strain as with other strain ribotypes: age > 65 years (aOR = 1.77, 95%CI: 1.31-2.4) and fluoroquinolone use (aOR = 1.96, 95%CI: 1.37-2.80) [74] . The one study with the highest report of no antibiotic exposure (96%) was also mostly community cases [75] . Exposure to infected room-mates or proximity pressure has been reported by several studies in adult CDI (Table 2 ), but not in children, which may be due to the lack of HCFA outbreaks reported in pediatric hospitals. The literature presents different results for proton-pump inhibitors, some showing significant risk, while others do not ( Table 2) .
Comparison of epidemiology of pediatric and adult AAD: The overall median incidence of pediatric AAD averages 27/100 compared to 15/100 for adult AAD, but the range in both populations is wide (< 1%-80%), as shown in Table 1 . The incidence from these studies may be confounded by method the data was collected and from differences in the age distributions, the types of antibiotic exposures and whether the antibiotic exposure occurred while the patient is hospitalized or as an outpatient. Data for secular trends of pediatric AAD and adult AAD have not been documented, so it is uncertain if non-C. difficile related AAD is increasing or decreasing over time. Limited data is available on non-C. difficile etiologies of AAD and, without having a pathologic etiology to link time of occurrence and place, it is impossible to establish the existence of non-C. difficile outbreaks of AAD for both pediatric and adult cases of AAD. It is difficult to compare risk factors for pediatric vs adult AAD due to the lack of studies for AAD risk factors.
Comparison of epidemiology of pediatric and adult CDI: While the overall median incidence from Table 1 of pediatric CDI (31/10000) may be higher than adult CDI (10/10000), these rates are highly influenced by method in which the data was collected, differences in age distribution, setting (inpatient or outpatient) and underlying risk factor distribution. National, prospective surveillance studies of CDI rates have only recently become established. The prevalence of CDI is not constant over all age ranges; pediatric CDI peaks at age 5, while adult CDI peaks at age 67. The increase in pediatric CDI in early childhood may be due to an increase in antibiotic use, especially associated with respiratory infections and perhaps to exposure to other children in schools and daycare settings. Adult cases of CDI may increase with age due to the development of more chronic co-morbidities, higher rates of hospitalizations and increased exposure to antibiotics with age. Generally, more CA cases are reported for pediatric CDI (41%) compared to adult cases of CA-CDI (30%). The rate of CA-CDI is increasing, especially in children. Significantly more adult CDI cases are female (median of 56%) compared to female pediatric cases (median of 47%, P < 0.01). There have been few studies that have reported outbreaks of pediatric cases of CDI, while large outbreaks of CDI in adult inpatients are commonly reported. One difference between adult and pediatric CDI populations is the higher prevalence of the hypervirulent epidemic C. difficile strain NAP1/027/ BI in adult patients. This may be due to the restriction of fluoroquinolone use in children, as this antibiotic is a risk factor for NAP1/027/BI CDI in adults. Some risk factors are similar for pediatric and adult CDI: age and exposure to antibiotics. In contrast, while prior hospitalization is an established risk factor for adult CDI, its role in pediatric CDI is unclear, especially as pediatric CA-CDI rates continue to increase. Adults with CDI have a more complex risk factor profile than pediatric CDI.
CLINICAL PRESENTATION
Incubation time
Pediatric AAD incubation time: The mean incubation times for pediatric AAD is from 2-6 d, with AAD typically occurring while the children are on antibiotics (85%-92% of cases); only 8%-15% report delayed-onset AAD post-antibiotics (Table  3) . For example, in 225 outpatient children given antibiotics, the mean onset was 2.3 ± 1.1 d and all cases of AAD occurred while the children were taking the antibiotics [76] . The time of onset is similar for outpatients (2-5 d) [63, 76] and for inpatients (4-6 d) [77, 78] .
Adult AAD incubation time:
The mean incubation time for adult AAD cases is 3-18 d, but the time of onset (while on antibiotics vs delayed-onset) was not as consistently reported as in studies of pediatric AAD. Studies with lower rates of delayed-onset AAD tend to suffer from an insufficient follow-up after antibiotics were discontinued [79, 80] . In one controlled trial of adults on antibiotics randomized to a probiotic drink or control group, only 5 (26%) of the 62 control patients developed AAD while on antibiotics, while most (74%) had delayed-onset AAD [81] . The incubation period of AAD is related to time of normal flora recovery after antibiotic exposure. In one study of six healthy adult volunteers exposed to oral amoxicillin (1.5 g/d for 5 d), a major shift in the normal flora was detected within 24 h after antibiotic exposure; 88% of the normal flora recovered within 30 d and only 89% recovered after 60 d [82] . One case of an adult patient with amoxillcin-clavulanic acid treatment was followed for changes in normal flora [83] . After day four of antibiotic exposure, there was a complete absence of Clostridium cluster XIVa (down from 20% from day 0) and the presence of Faecalibacterium decreased from 33% to 15%. These two taxa are the main ones associated with the production of butyrate (the preferred energy source of colonocytes). The intestinal microflora of three healthy adult human volunteers was characterized using 16S rRNA sequencing before and after exposure to ciprofloxacin (500 mg bid for 5 d). Ciprofloxacin impacted 33% of the bacterial taxa in gut, reducing both diversity and taxonomic richness. Taxonomic composition mostly recovered within 4 wk postantibiotic exposure, but several taxa failed to recover within 6 mo. Ciprofloxacin was found to reduce 30% of the taxa in these individuals [84] .
Pediatric CDI incubation time:
The mean incubation period for pediatric CDI is 3-10 d, as shown in Table  3 [71, 85] .
Adult CDI incubation time:
The mean onset of the 2.4 (1-8) d Mitchell [85] 3.7 ± 2.6 d Duman [158] 10 d Pai [71] 6 d Chang [86] 4.0 ± 4.3 d Corrêa [77] 7 d Hickson [81] 10 d James [197] 4.9 ± 2.5 d Shan [93] 8 d (1-30 d) Lusk [36] 12 d Figueroa [90] 4.9 ± 3 d Kotowska [157] 9 ± 1 d Yapar [80] 13 d Wenisch [102] 5.3 ± 3.5 d Turck [63] 16 d (6-60 d) Pozzoni [160] 6.2 ± 4.2 d Ruszczyński [78] 18 d McFarland [96] Time of Onset (while on antibiotics vs delayed-onset postantibiotic)
85% vs 15% Turck [63] 26% vs 74% Hickson [81] 80% vs 20% Duleba [18] 23% vs 77% Chang [86] 92% vs 8% Corrêa [77] 27% vs 73% McFarland [96] 38% vs 62% Pozzoni [160] 71% vs 29% Can [79] 75% vs 25% Duman [158] 85% vs 15% Yapar [80] Severity of disease Duration 2.6 ± 1.1 d Damrongmanee [76] 1-6 d Allen [159] 2 d Denno [97] 5.4 ± 1.8 d Ouwehand [163] (mean ± std. dev.) or median (range) days 3.9 ± 2.3 d Destura [172] 2-25 d McFarland [96] 2-9 d McFarland [1] 6.6 d Wenisch [102] 4 ± 3 d Turck [63] 3 (2-5) d Pozzoni [160] 6 d Crews [12] 13 ± 13 d McFarland [89] 4.1 ± 2.1 d Ruszczyński [78] 4.4 ± 2.5 d Dietrich [23] 7-8 d Duleba [18] 13 ± 7.4 d Morrow [198] 5 ± 2.8 d Corrêa [77] 4.9 ± 2 d de Souza [139] 26 ± 56 d Hsu [103] 9 ± 1 d Shan [93] 5.4 ± 1.8 d Ouwehand [163] 21.5 (1-72) d Lusk [36] Asymptomatic carriers NR NR 26% Sandora [66] 6% Jarvis [175] 35% Enoch [196] 9.4% Bruns [199] 45% Rousseau [53] 9.7% Leekha [200] 67% Delmée [49] 61% McFarland [45] Mild-moderate diarrhea
Most common
Most common 23% Pai [71] 35% McFarland [201] 66% Schwartz [176] 48% Ramanathan [202] 71% Na [13] 59% Jardin [206] 72% Wendt [4] 61% Kyne [101] 87% Khanna [40] 61% Bartlett [207] Severe disease Rare 16% Gogate [94] 8% Wendt [4] 3% McFarland [201] 12% Khanna [40] 3% Rubin [208] 21% Crews [12] 8% Bartlett [207] 27% Schwartz [176] 9% El Feghaly [182] 76% Pai [71] 16.4% Pepin [106] 18% Wenisch [102] 18% See [185] 34% Khanna [209] 47% Jardin [206] 52% Ramanathan [202] PMC 1 case Vidrine [95] 1% Lusk [36] 0.1% Wendt [4] 0.1% Wenisch [102] 1.6% Duleba [18] 1% McFarland [201] 4.9% Kim [98] Toxic megacolon NR NR 1 case Castillo [99] 0.1% Wenisch [102] Fulminant disease NR NR rare Qualman [203] 2% Dallal [108] n = 4 Rivlin [204] 4% Sailhamer [210] 6% van de Wilden [211] Recurrent disease NR 28% de Souza [139] 10% Sandora [66] 18.8% Wenisch [102] 11% Wendt [4] 21% Vesteinsdottlir [73] 16.5% Crews [12] 22% Eyre [118] 17% Nylund [181] 22% Ramanathan [202] 17% Schwartz [176] 27% McFarland [121] 20% Khanna [40] 29% Wullt [122] 22% Nicholson [205] 29% Khanna [17] 24% Kim [98] 36% Drudy [212] 31% Morinville [100] 42% McFarland [89] References are given by last name of first author and citation number in brackets. AAD: Antibiotic-associated diarrhea; CDI: Clostridium difficile infections; NR: Not reported; PMC: Pseudomembraneous colitis.
initial episode of adult CDI cases is 6-12 d (Table 3) , although delayed-onset (> 21 or 31 d post-discharge) has been reported in several studies ranging from 10%-53% of CDI cases [45, 86, 87] .
Time between recurrent episodes of CDI:
The time between adult CDI recurrences has been reported in several studies, but there are no reports of this time interval in pediatric CDI. In 24 adults with C. difficile colitis, the mean time between episodes was 69.6 ± 42.2 d, ranging from 3-32 d post-vancomycin treatment [88] . In another study of 209 adults with recurrent CDI, the mean time between episodes was 69.6 ± 42 d [89] . Figueroa et al [90] reported the mean time to recurrence was 12.2 ± 6.4 d. Mean time to CDI recurrences in a mixed pediatric and adult population (aged 1-96 years old) was 42 d, and ranged from 10-211 d [91] .
Severity
Pediatric AAD severity: The definition of severity of disease for diarrhea has been well documented for adults, but is less standardized for pediatric cases.
Most clinical trials define pediatric diarrhea as one to three abnormally loose stools per 24 to 48 h [19, 20, 21, 92] . Additionally, stool frequency is more difficult to quantify in diaper-aged children. The reported mean duration for pediatric AAD is 3-9 d (Table 3) [63, 76, 93] . The severity of pediatric AAD ranges from mild, selflimited diarrhea to moderate diarrhea (Table 3 ). In one study of 250 pediatric inpatients (5-12 years old) who developed diarrhea, most (82%) were not due to C. difficile, but 16% had severe diarrhea, 36% had abdominal pain and 11% reported vomiting [94] . If the symptoms of diarrhea are severe (> 10 movements/ d), pediatric AAD may lead to electrolyte disturbances and dehydration [94] . Few cases of pediatric antibioticassociated colitis or pseudomembranous colitis (PMC) have been reported. There is one case report of a 16 year old girl who developed PMC not associated with C. difficile [95] . Adult AAD severity: Frequency of diarrhea, colitis and PMC associated with adult cases of AAD (not due to C. difficile) are infrequently reported. The mean duration of adult AAD is 1-22 d (Table 3) . From one study, the mean duration adult AAD was four days while on antibiotics, but the mean duration was longer (18 d) if the cases were delayed-onset AAD [96] .
Pediatric CDI severity:
The range of symptoms for pediatric CDI is wide: children can develop mildmoderate diarrhea or severe disease or recurrent episodes of CDI (Table 3) . Most symptoms of pediatric CDI are mild-moderate diarrhea (23%-87%) [13, 40] .
The mean duration of pediatric CDI is not as well documented in the literature, but ranges 2-9 d based on limited reports (Table 3) [1, 12, 97] . A population-based surveillance study of pediatric CDI cases found 87% reported only diarrhea, 9% had severe CDI and 4% had severe CDI with complications [40] . Severe cases of pediatric CDI (defined variously as having > 2 severe indicators including fever, leukocytosis, requirement for ICU stay or surgery) have been reported in 8%-76% of cases (Table 3) . Disease severity in pediatric CDI may be overestimated if adult criteria are used. In two studies reporting a high frequency of severe CDI in children, a re-assessment found the majority had low rates of morbidity and mortality and were successfully treated with standard antibiotic therapy [71, 98] . Kim et al [98] defined severe pediatric CDI as having at least one complication (PMC, CDI-related surgery, intestinal perforation, toxic megacolon, or ICU stay) or ≥ 2 laboratory/clinical indicators (elevated white blood cell count, or high albumin, or high creatinine, fecal blood or fever). Pai et al [71] defined severe pediatric CDI if any of the following were present: elevated white blood cell counts, rising serum creatinine, fever or signs of severe colitis. Hence new criteria for determining diarrhea severity in pediatric CDI are being studied. Infrequently, very severe forms of pediatric CDI have been reported. A case of CDI in a four year-old boy who had been treated with amoxicillin-clavulanic acid developed toxic megacolon [99] . Recurrences of pediatric CDI are common (10%-31% recurrence rates, as shown in Table 3 ), which may result in longer hospitalizations if the child is an inpatient [40, 91, 100] . Rates of recurrent CDI were found to be higher in children with severe CDI (31%) compared to a lower frequency (15%) if the child had mild-moderate CDI [98] . Adult CDI severity: Mild to moderate diarrhea is seen in 35%-61% of adult CDI cases, while severe disease occurs less frequently (3%-41%), as shown in Table 3 . In one study of 73 adult CDI cases, 18 (25%) had mild, self-limiting disease, 26 (36%) developed moderate diarrhea, 23 (31%) developed prolonged diarrhea and 6 (8%) developed complicated CDI [101] . The reported mean duration of adult CDI ranges from 5-26 d (Table 3 ) [89, 102, 103] . Adults with severe CDI report abdominal pain and fever in addition to diarrheal symptoms [104] . Attributable mortality is significantly higher in adult patients with severe CDI compared to mild-moderate CDI (60% vs 28%, P = 0.046, respectively) [105] . A hypervirulent strain of C. difficile (NAP1/027/BI) was the predominant strain associated with outbreaks of CDI cases in 88 hospitals in Quebec Canada in 2003-2004 which were associated with twice the rate of severe CDI cases with higher mortality rates [106] . More recent surveillance studies for endemic cases across 10 United States states also found a significantly elevated risk of severe CDI with the NAP1/027/BI strain [107] . Fortunately, the most severe forms of CDI (pseudomembranous colitis, toxic megacolon or fulminant disease) are infrequently reported (1%-6%). Fulminant CDI is a systemic inflammatory syndrome that occurs infrequently, but typically requires colectomy and often results in death [108] . Although diarrhea is the hallmark of CDI, it may be absent in fulminant CDI, secondary to severe colonic dysmotility making fulminant colitis difficult to diagnose [109, 110] . Recurrent CDI may occur in 19%-42% of adults after their initial episode of CDI has resolved, as shown in Table 3 . As many as 10%-30% recur once after an initial CDI episode, 40% have two recurrences and 50% of those continue to have multiple recurrences, which may occur over a period of several years [111] . The CDC estimates in the United States during 2011, 483120 had initial CDI episodes and an estimated 77000-232000 would have recurred, providing a conservative national estimate of 715000 cases of total CDI/year [9] .
Comparison of clinical presentations of pediatric and adult AAD:
The onset of pediatric AAD appears to be slightly quicker than adult cases of AAD and most pediatric AAD cases become symptomatic while the child is on antibiotics. In contrast, more cases of delayed-onset adult AAD cases are reported. However, whether this is a valid observation or due to the infrequent follow-up of children with antibiotic exposure is unknown. Most AAD cases are mildmoderate both in pediatric and adults. Pediatric cases of AAD and CDI typically have a shorter duration than adult cases of AAD and CDI.
Comparison of the clinical presentation for pediatric vs adult CDI:
The onset of CDI is fairly rapid for pediatric cases (3-10 d), while symptoms appear slightly later in adult CDI (2-15 d) and recurrences of adult CDI may appear within two months of the previous episode. Pediatric and adult cases of CDI are both typically mild-moderate disease and the frequency of severe disease is similar for pediatric and adult cases, despite the finding that the hypervirulent strain of BI/NAP1/027, which is associated with severe CDI, is rarely found in children. However, severe complications of CDI, especially fulminant CDI and PMC, are more common in adults and are rarely seen in pediatric CDI. Recurrent CDI is slightly more common in adults (averaging 25%) than for pediatric CDI (averaging 20%).
CONSEQUENCES OF INFECTION
Pediatric AAD consequences
The consequences of pediatric AAD for inpatients may include increased length of hospitalization and, for outpatients, parents may discontinue the inciting antibiotics due to the diarrhea, without fully treating the child for the inciting infection [76] . Other consequences of pediatric AAD have rarely been reported (Table 4) .
Adult AAD consequences
Prolonged length of stay and higher mortality rates have been reported for adult AAD cases [37, 112] . Several studies have estimated that the cost of healthcare associated with adult AAD ranges from $1400-$1968/ person [113, 114] . As with pediatric cases, development of AAD may also lead to premature discontinuation of antibiotic therapy, resulting in low cure rates [37] .
Pediatric CDI consequences
Consequences of pediatric CDI may include increased length-of-stays for inpatients, increased mortality, rates of surgery (colectomies), higher healthcare costs, and re-admissions to healthcare systems, as shown in Table 4 . Crude mortality rates (1%-5%) and CDI attributable mortality rates (2%-3%) are also low. Caution should be used when comparing mortality rates, as the observation periods vary from just during hospitalization stays [44, 69] , to 2-3 mo [71, 115] to 6 mo [12] , or were not reported [14, 100] . Even though the proportion of severe CDI can be higher in children, the requirement for colectomy is low (approximately 1%) in mild-moderate CDI. However, the rate can be higher in cases of severe CDI. In one study of 151 children with severe CDI, 8.6% required colectomies with a 50% associated mortality rate [116] . The median cost for healthcare for pediatric CDI is not trivial ($19000-$32000/child). As an increase in incidence rates of pediatric CDI was observed from 1997-2006, there were also increases seen for costs for healthcare (averaging $20000/case) and an increased risk of colectomies [14] . In a survey of CDI in 22 Children's hospitals in United States from 2004-2006, 26% of the 4895 inpatient CDI cases were children < 1 year old and 1.2% required colectomies. The all-cause 60-d mortality rate among pediatric patients was reported to be 4% in a study of 22 pediatric hospitals surveyed [115] . Costs for healthcare associated with pediatric CDI are generally > $20000 United States dollars. Additional increases in length of hospitalizations are also observed for pediatric CDI cases (Table 4) ranging from 4-23 additional days, which may explain the higher healthcare costs associated with this disease. 
Premature stop of antibiotic therapy
Yes Damrongmanee [76] 4% Elseviers [37] NR NR Dehydration NR 17% Elseviers [37] 75% Duleba [18] NR Attributable mortality NR NR 2% Despandi [169] 5.7% Dubberke [213] 2.2% Sammons [44] 5.7% Gravel [119] 3% de Blank [69] 4.5% Tabak [117] 6.3% Vesteinsdottir [73] 6.9% Loo [57] 15% McFarland [121] 17% Pépin [58] Crude mortality NR 3.6% Selinger [112] 1% Morinville [100] 10% Tabak [117] 2% Nylund [14] 16.5% Wenisch [102] 3.8% Kim [115] 28% Bacci [120] 4.6% Crews [12] 35% Eyre [118] 5% de Blank [69] 38% Dubberke [213] 5.4% Pai [71] Colectomy NR NR 0.1% Wendt [4] 0.3% See [107] 0.9% Despandi [169] 0.7% Halabi [214] 0.9% Nylund [14] 1.2% Dallal [108] 1% Pai [71] 2% McFarland [121] 1.2% Kim [115] 6.2% Muto [59] 9.1% Jarvis [175] Cost NR $1400 Song [113] $18900-$93000 Sammons [44] $3103 McFarland [89] ($/patient) $1968 Kamdeu [215] $28404 Despande [169] $3427-$33055 Kwon [10] $31957 Nylund [14] $3427-9960 1 Dubberke [216] $7179 Dubberke [217] $11631 2 Dubberke [216] $11353 3 Lawrence [124] $23643 Tabak [117] Length of stay (days additional stay) NR 8.5 d Elseviers [37] 4 d Despande [169] 3 d Lawrence [124] 4 d Nylund [14] 4 d Dubberke [217] 6 d Sammons [44] 6 d Vesteinsdottir [73] 23d de Blank [69] 10 d Abdelsattar [218] 13 d Tabak [117] 14 d Crabtree [184] 16 d Zerey [193] 24 d McFarland [121] Re-admissions NR 8% Pozzoni [160] NR 21% McFarland [121] 39% Abdelsattar [218] 52% Dubberke [213] Adult CDI consequences
As with pediatric CDI, the consequences of adult CDI may also include increased mortality, higher rates of surgery (colectomies), higher healthcare costs, longer length-of-stays for inpatients and re-admissions to healthcare systems (Table 4) . Reported crude mortality rates can be high (10%-38%), and CDI attributable mortality ranged from 6%-17%. As with pediatric studies, the follow-up for mortality ranges from only during hospitalization [117, 118] , to 30 d [57, 58, 102, 119, 120] , to 60 d [121] , to 90 d [73] , or to 6 mo [122] . Adult CDI was sufficiently severe to require colectomy in only 1%-9% of patients, but the mortality associated with this type of surgery is of clinical concern. A meta-analysis of 31 studies of adults with CDI found overall, 1.1% needed a colectomy, but the rate increased to 30% if it was a severe case of CDI and post-colectomy mortality was exceedingly high (41%) [123] . Colectomy rates range from 0.3%-1.3% of CDI cases during outbreaks and 1.9%-6.2% during endemic periods [10] . The healthcare costs of adult CDI ranges from $3427-$9960 for initial episodes of CDI and costs may reach as high as $33000 for recurrent cases [9, 124] . The cost of adult CDI care was determined from 2012 HCUP data and ranged from $3427 to $33055/patient, depending if it is an initial or recurrent CDI case and the total CDI 1 For initial CDI episodes only; 2 For recurrent CDI episodes only; 3 In intensive care unit. References are given by last name of first author and citation number in brackets. AAD: Antibiotic-associated diarrhea; CDI: Clostridium difficile infections; LOS: Length of stay; NR: Not reported. [219] Antibiotic stewardship NR NR NR 46% Wenisch [102] (% CDI reduced) 66% Kallen [220] Probiotics S. boulardii (pRR = 0.43)
McFarland [19] S. boulardii (pRR = 0.47)
McFarland [131] S. boulardii (pRR = 0.25)
McFarland [138] La+Lc+Lr (pRR = 0.21) Johnson [137] L. rhamnosus GG (pRR = 0.36) McFarland [19] S. boulardii (pRR = 0.49) Szajewska [132] S. boulardii (pRR = 0.25) Szajewska [132] La+Lc+Lr (pRR = 0.21) McFarland [138] S. boulardii (pRR = 0.43) Szajewska [132] La+Lc+Lr (pRR = 0.51) Hempel [129] L. casei DN114001 (pRR = 0.08) McFarland [138] L. rhamnosus GG (pRR = 0.48) Szajewska [132] L. rhamnosus GG (no) Szajewska [132] S. boulardii (no) Szajewska [132] Treatment
Initial episode
1
No treatment given or stop inciting antibiotic (% done) NR 4% Elseviers [37] 0% Khanna [40] 10% Vensteinsdottir [73] 4% Kim [98] 20% Duleba [18] 24% McFarland [121] 53% Pai [71] 53% Huang [65] 69% Gogate [94] Oral rehydration therapy (% cured) 21% Shan [93] 17% Elseviers [37] NR NR Metronidazole NR NR 31% Gogat [94] 75% Vesteindottlir [73] (% cured) 69% Morinville [100] 82% Khanna [40] 84% Zar [145] 90 Pai [71] 86% Kim [221] 93% Kim [98] 94% Wenisch [222] 97% Duleba [18] Vancomycin NR NR 83% Duleba [18] 91% Kim [221] (% cured) 85% Jardin [206] 94% Cornely [141] 100% Khanna [40] 94% Wenisch [222] 97% Zar [145] 100% Vesteindottlir [73] Severe disease (% cured) NR NR NR 97% vanco vs 76% metro Zar [145] Probiotics (% cured)
Ligny [140] NR S. boulardii (19%, ns)
McFarland [111] Monoclonal antibodies NR NR NR 93% (P = 0.07) Lowy [146] (% cured) Recurrent disease 1 Metronidazole NR NR NR 33% Wullt [223] (% no further recurrences) 50% Surawicz [142] 58% McFarland [143] 80% Vesteindottlir [73] Vancomycin NR NR NR 46% (10 d) McFarland [143] (% no further recurrences) 55% Surawicz [142] 69% (taper) McFarland [143] 86% (pulse) McFarland [143] 100% Vesteindottlir [73] Fidaxomycin NR NR NR 86% Cornely [147] (% no further recurrences) Probiotics NR NR NR S. boulardii (65%)
McFarland [111] (% no further recurrences)
S. boulardii with high dose vanco (83%) Surawicz [142] Fecal replacement therapy NR NR NR 81% van Nood [224] (% no further recurrences) 90% Cammatora [225] costs for United States during 2012 ranged from $1-$6 billion dollars [10] . For cases of adult HCFA-CDI cases, hospitalization was typically prolonged from 3-24 d (Table 4 ). For adults with CDI, the likelihood of being re-admitted to a healthcare facility is high (21%-52%), especially for patients with recurrent CDI.
Comparison of pediatric and adult consequences for AAD or CDI
A consequence of pediatric CDI may include dehydration, especially for younger children, unlike adults. Pediatric cases of CDI have lower mortality rates and less frequent rates of colectomies. However, for both pediatric and adult CDI, if symptoms are sufficiently severe to require colectomy, there are high mortality rates associated with this type of surgery. For inpatients, development of CDI is associated with longer lengths-of-stay and its associated increased cost of care.
PREVENTION
Prevention of pediatric AAD
Prevention of AAD has traditionally relied on appropriate use of antibiotics, for instance, limiting the use of broad-spectrum antibiotics whenever possible. However, studies documenting the impact of these practices on pediatric AAD are lacking (Table 5) . AAD results from the disruption of the normal, protective microbes in the intestine caused by unintended killing of non-pathogenic organisms by the antibiotics. Probiotics (living microbes, which when given at a sufficient dose, having a proven health benefit on the host) may be given at the same time as the antibiotics to prevent the development of AAD by helping to stabilize the normal microbiome [125] . Caution should be exercised to not give a bacterial strain of probiotic that is susceptible to the prescribed antibiotic. This is not of concern if the probiotic is a yeast strain. Of 17 different types of probiotics tested for AAD, only a few strains have evidence-based efficacy for preventing pediatric AAD [126, 127] . A meta-analysis of 22 randomized controlled trials testing various probiotics for the prevention of pediatric AAD found only two types of probiotics were significantly effective for pediatric AAD: a yeast, Saccharomyces boulardii CNCM I-745 (S. boulardii) (pooled RR = 0.43, 95%CI: 0.32-0.60) and a bacterial probiotic, Lactobacillus rhamnosus GG (pooled RR = 0.36, 95%CI: 0.19-0.69) [19] . Other meta-analyses (Table 5 ) have confirmed this finding.
Prevention of adult AAD
Of 20 different probiotic types tested for the prevention of adult AAD, only a few have solid evidence for efficacy (Table 5 ). Videlock et al [128] pooled the results from 24 randomized controlled trials in adults and found in general, probiotics were effective in preventing AAD (pooled RR = 0.53, 95%CI: 0.43-0.66), but they did not report which strain(s) were independently protective. Many metaanalyses have reported combined data from a mixed population of adults and children or mixed types of probiotic strains [129, 130] . One method to determine which probiotic strain is more effective is to only use data from one type of probiotic, or use sensitivity analysis to assess the effectiveness, grouping trials by the same strain of probiotic. A meta-analysis of 10 randomized controlled trials using only S. boulardii for the prevention of adult AAD found significant efficacy for this probiotic (pooled RR = 0.47, 95%CI: 0.35-0.63) [131] . Another meta-analysis pooled 15 trials and confirmed S. boulardii is effective for preventing adult AAD [132] . Hempel et al [129] conducted a metaanalysis of probiotics for AAD, but pooled 62 trials (32 different types of probiotics) that were a mixture of adult and pediatric populations and also mixed strains within some probiotic sub-groups. Their "Lactobacillus" subgroup contained many different strains of Lactobacilli, but extracting three trials in adult patients and limiting the pooled results to one type of probiotic [35] reviewed six trials for the prevention of AAD in elderly adults. Only one type of probiotic (B. licheniformis) in one trial was found to be effective, although the amount of evidence in the elderly population is extremely limited. Another meta-analysis pooled the data from six trials in adults randomized to either L. rhamnosus GG or placebo and did not find that this probiotic was effective to prevent adult AAD [133] . Although the data for the prevention of adult AAD by probiotics is extensive, the challenge is having sufficient numbers of clinical trials for each type of probiotic strain to allow a valid conclusion to be formulated.
Prevention of pediatric CDI
The prevention of CDI is typically targeted at a common source of infection (healthcare facilities) and relies upon a multi-pronged approach of infection control programs, antibiotic stewardship and measures to support the host's defenses. However, since HCFA pediatric CDI is not common, prevention of community-based CDI needs to rely on rational use of antibiotics and the use of probiotics. There are no studies of HCFA infection control programs in pediatric hospitals. The use of probiotics has been investigated in the pediatric population at risk. In one study of 283 children receiving antibiotics for respiratory infections, only 0.7% randomized to S. boulardii CNCM I-745 developed CDI compared to 5.6% of those given placebo, P = 0.04 [93] . A meta-analysis of probiotics for the prevention of CDI was done, pooling the results of three pediatric trials and found probiotics reduced the incidence of pediatric CDI by 60% (pooled RR = 0.40, 95%CI: 0.17-0.96) [134] . However, this analysis was limited by the small numbers of trials done per probiotic strain in pediatric patients. Another meta-analysis and systematic review of probiotics for pediatric CDI was also limited by the scarcity of controlled trials in this population. Although the pooled data from five randomized controlled trials showed probiotics, in general, were protective of pediatric CDI (pooled RR = 0.35, 95%CI: 0.13-0.92), four types of probiotics had no second, confirmatory trial, and only S. boulardii showed efficacy using data pooled from two trials (Table 5 ) [19] .
Prevention of adult CDI
Current guidelines recommend a bundled program of surveillance, contact precautions, CDI patient isolation, hand hygiene, use of disposable equipment when possible and environmental disinfection [2, 135] . Rampant inappropriate antibiotic use was documented in the 1990-2000's in hospitalized patients and outpatients, and while antibiotic stewardship programs reduced this rate, one recent study still found 74% of antibiotics given to 126 inpatients with CDI were inappropriately prescribed [136] . There have been many studies showing the use of a multi-disciplinary infection program resulted in a decrease of adult CDI cases. One important foundation of these programs is the use of antibiotic stewardship oversight, which has been shown to reduce CDI rates in adult inpatients from 46%-66% (Table 5) . Probiotics have also been tested to assess if they can be effective for preventing adult cases of CDI. A meta-analysis of 11 randomized controlled trials for the prevention of CDI tested five different types of probiotics and found only one mixture of probiotics (L. casei, L. acidophilus and L. rhamnosus, "BioK+") had a significant preventive effect (pooled from three trials, RR = 0.21, 95%CI: 0.11-0.42), while the pooled data from four trials using S. boulardii was not effective (RR = 0.70, 95%CI: 0.29-1.69) [137] . The other four trials did not have confirmatory trials and were excluded. A more recent meta-analysis of 21 randomized trials testing probiotics for CDI found four types of probiotics were significantly effective for preventing CDI, but when pediatric trials were excluded, only two probiotic types were effective in adults: L. casei DN114001 "Actimel" [pooled from two trials (RR = 0.08, 95%CI: 0.01-0.63) and a mixture of L. acidophilus and L. casei and L. rhamnosus "BioK+" (pooled from three trials with four treatment arms, RR = 0.21, 95%CI: 0.08-0.58) [138] .
Comparison between prevention strategies for pediatric vs adult AAD and CDI
Prevention of pediatric and adult AAD may rely on rational use of antibiotics, but there have been no studies testing this intervention in pediatric or adult patients. There are studies of preventive strategies for adult CDI that include improved infection control programs focused on limiting C. difficile transmission at healthcare facilities, in addition to antibiotic stewardship programs to limit unnecessary or inappropriate antibiotic use. The data is supportive for the use of these programs to prevent adult CDI, but studies are lacking for pediatric populations. The use of preventive probiotics is supported by studies and children and adults seem to respond differently to the type of probiotic strain depending upon the outcome to be prevented. To prevent AAD, children responded better to S. boulardii or L. rhamnosus GG, while adults responded better to S. boulardii or the multi-strain mix of three Lactobacilli called "BioK+". To prevent CDI, S. boulardii was effective in pediatric patients, while BioK+ or L. casei DN114001 worked well in preventing adult CDI cases.
TREATMENT
Treatment for pediatric AAD
Current treatment for pediatric AAD usually involves discontinuation or changing the type of the inciting antibiotic and giving oral rehydration therapy. As the etiology is typically only known for a proportion of the cases (approximately 1/3 is due to C. difficile), effective antibiotic treatment for AAD is limited. If the diarrhea is moderate-severe, oral rehydration therapy may be sufficient to assist spontaneous recovery [93] .
Treatment for adult AAD
Current treatment for adult cases of AAD usually involves discontinuation or changing the type of the inciting antibiotic (Table 5 ). In one study of 743 hospitalized adult patients in four Belgian hospitals who were given antibiotics, AAD developed in 71 (9.6%), with only four patients positive for C. difficile. Of the 71, only 46 (65%) were treated for AAD: IV hydration (24%), patient isolation (22%), probiotics (20%), antidiarrheal medications (20%), metronidazole (6%), discontinuation of the inciting antibiotic (6%), or other antibiotics (2%) [37] . Very few randomized controlled trials have been done to treat adult cases of AAD, including those assessing the use of probiotics. One trial compared a mixture of L. casei and Bifidobacterium breve with placebo in 70 adults with AAD and found no significant difference in the duration of AAD (4.9 d vs 4.5 d, respectively) [139] . Another study randomized 20 adults with mild AAD to either S. boulardii or placebo and found significantly more were cured with S. boulardii (70% vs 10%, P < 0.01, respectively) [140] . No other trials for the treatment of adult AAD have been reported.
Treatment for pediatric CDI
Discontinuation or changing the type of the inciting antibiotic is still recommended as the first step for treating mild pediatric CDI, along with oral rehydration therapy if the diarrhea is severe [71] . For children with moderate CDI, empirical antibiotic treatment directed against C. difficile is recommended. The first choice of treatment is oral metronidazole (20-40 mg/kg per day), followed by oral vancomycin (40 mg/kg per day) given orally or by enema if they do not respond to metronidazole [1] . In one study of 4895 inpatient pediatric CDI cases, 74% responded to metronidazole or vancomycin treatment [115] . Most studies have enrolled children with their first episode of CDI (Table 5) and show effective cure rates with either metronidazole (ranging from 31%-97%) or vancomycin (ranging from 83%-100%). No studies on treatments have included children with recurrent CDI disease.
Treatment for adult CDI
Treatment for the initial episode of adult CDI typically relies upon one of three antibiotics, while treatment of recurrent CDI may require adjunctive use of probiotics or immune stimulators. Once CDI has been diagnosed in adults, treatment with antibiotics directed against C. difficile is recommended (metronidazole or vancomycin or fidaxomicin) [2, 28, 141] . For mild to moderate CDI or for initial episodes of CDI, the recommended dose of metronidazole is 500 mg, three times daily and for vancomycin the dose is 125 mg four times daily, but if there is no response or if the CDI is severe, higher doses of vancomycin can be used (up to 2 g/d) [2, 142, 143] . Failure to respond to the antibiotic used within 5-7 d should prompt the switch to the other type of antibiotic. A meta-analysis of 15 treatment trials for adult CDI found vancomycin has a higher cure rate (mean 88% ± 9.1%) compared to metronidazole (76% ± 11.3%) and a lower rate of CDI recurrences (13% ± 9.9% and 31% ± 44%, respectively) [144] . For severe cases of adult CDI, treatment with vancomycin has been found to be more effective than metronidazole (97% cured vs 76% cured, respectively) [145] .
Treatment recommendations vary according to whether the CDI episode is an initial episode, or if the patient has recurrent CDI disease and Table 5 presents the effectiveness of various treatments for studies that provide data separately for initial vs recurrent CDI disease. Vancomycin has slightly higher cure rates (91%-100%) for adults with initial CDI compared to metronidazole (75%-94%). Fidaxomicin was found to be equivalent to vancomycin for the initial episode of CDI in adult patients [141] . One study using monoclonal antibodies against C. difficile showed a trend (P = 0.07) for better cure rates (93%) compared to placebo (82%) for the initial episode of CDI [146] . From 20%-60% of adults treated with antibiotics have at least one recurrence of CDI, and many suffer from repeated recurrences that may occur over a period of years [143] . Effective treatments for adult recurrent disease have included vancomycin (55%-100% cured), while metronidazole seems to be less effective (50%-80% cured). Fidaxomicin was shown to successfully treat recurrent CDI, when it reduced the recurrence rate to 14% compared to 26% in vancomycin [147] . The first recurrence should be treated with a repeated 10-d course of vancomycin, while the subsequent recurrences are recommended to be treated with pulsed or tapered vancomycin regimes or use an adjunctive probiotic [2] . In one study of 163 adults with recurrent CDI, higher cure rates were noted for treatment with vancomycin pulse (86%) or vancomycin taper (69%) compared to a single 10-d vancomycin (46%) or metronidazole (58%) regime [143] . By the end of therapy, vancomycin was more effective at clearing C. difficile culture and/or toxins (89%) than metronidazole (59%, P < 0.001). The evidence for probiotics to treat adult CDI is limited by the small number of randomized controlled trials for each probiotic strain. One type of probiotic, S. boulardii, has two trials which provide evidence that this probiotic may be effective for preventing recurrences of CDI in adults, especially if combined with high dose (2 g/d) vancomycin [131, 148] . Fecal microbial transplants (FMT) have been tested to treat adults with recurrent CDI and this method uses stool infusions from healthy donors containing a mixture of microbes [149] . Two controlled trials found significantly higher cure rates for those patients receiving FMT (81% and 90%) compared to the control patients (Table 5 ). Many other investigational treatments are being tested for adult CDI, including passive immunization using monoclonal antibodies and vaccines to C. difficile toxins, but the evidence is not yet conclusive [150] .
Comparison between treatments for pediatric vs adult AAD and CDI
The paucity of studies evaluating treatments for pediatric and adult AAD limits any conclusions, except to discontinue or switch the inciting antibiotic and use of oral rehydration therapy to prevent dehydration in children. To treat the initial episode of CDI, discontinuing the inciting antibiotic is more commonly seen in the pediatric patient compared to adults. Pediatric patients with initial CDI appear to respond slightly better to metronidazole, while adults respond slightly better to vancomycin. The choice should be balanced against the side-effects and toxicities of each antibiotic. For recurrent disease, the only studies that provided separate cure rates for metronidazole, vancomycin or fidaxomicin were in adult patients with recurrent CDI. Treatment with high doses of vancomycin, use of pulsed or tapered regimes of vancomycin, fidaxomicin or adjunctive use of some probiotic strains or FMT may be beneficial for adults with recurrent disease, but whether these treatments are effective in children with recurrent CDI has not been established.
CONCLUSION
This is the first comprehensive exploration comparing the similarities and differences of pediatric vs adult AAD and CDI. In summary, some of the major differences between pediatric and adult AAD and CDI relate to incubation periods, severity of the disease and treatment strategies. Most pediatric AAD/CDI cases become symptomatic while on antibiotics; in contrast, most adult cases have delayed-onset of symptoms that appear after the antibiotics have been discontinued and before the normal colonic microbiome has recovered. Pediatric CDI cases have lower mortality rates and fewer complications than adult CDI cases. Community acquired cases of CDI are more common in children, while most cases of adult CDI are associated with healthcare facilities. Adult CDI has a more diverse risk factor profile (more co-morbidities, types of hospital exposures, disruptive medications, etc.) than pediatric CDI, but both populations share increased risk for antibiotic exposure as a major risk factor. Pediatric CDI responds better to metronidazole, while adult CDI cases favor vancomycin. Recurrent CDI is reported more frequently in adults and treatment relies on a combination of antibiotic therapy and measures to restore the normal colonic microbiota including the use of probiotics or FMT.
Gaps in the knowledge base
By reviewing the literature, it became apparent there are several gaps in our knowledge about AAD and CDI. While national and global surveillance programs have been started for CDI to document incidence and trends over time, these programs have not been established for AAD. Basic demographic information (age, gender and race) and the spectrum of disease severity are infrequently reported for pediatric and adult cases of AAD. In addition, as the character of the intestinal microbiome shifts widely during the early childhood periods (neonatal, infant, pre-school, school-age, etc.) as children change nutritional status (bottle-fed, solid food, etc.) and are exposed to different environments (day-care, schools, etc.), a finer delineation of AAD and CDI disease data by age categories might illuminate how children respond to these diseases as these other types of life-factors change. Broadly pooling data by a 'pediatric' classification may be masking some agerelated responses. Sources of non-CDI associated AAD are difficult to determine due to the lack of documentation for specific etiologies. The lack of reported complications of pediatric and adult AAD may be due to either a true lack of disease progression, or due to the lack of adequate follow-up times for studies involving AAD. The lack of reported treatment studies for AAD and pediatric CDI requires further studies. It also would be interesting to determine if pediatric CDI is a risk factor when these children grow into adults. 
